4//SEC Filing
Forman Stephen J. 4
Accession 0001493152-20-022866
CIK 0001335105other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 6:07 AM ET
Size
14.2 KB
Accession
0001493152-20-022866
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Purchase
Common Stock
2020-11-30$4.75/sh+21,053$100,002→ 37,720 total(indirect: By Trust) - Purchase
Warrants to Purchase Common Stock
2020-11-30$4.75/sh+21,053$100,002→ 21,053 total(indirect: By Trust)Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (21,053 underlying)
Holdings
- 16,667
Options to Purchase Common Stock
Exercise: $0.96From: 2016-05-13Exp: 2021-09-13→ Common Stock (16,667 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common Stock (8,333 underlying) Common Stock
- 8,333
Options to Purchase Common Stock
Exercise: $0.90From: 2017-10-16Exp: 2022-10-16→ Common Stock (8,333 underlying) - 16,667
Options to Purchase Common Stock
Exercise: $0.96From: 2017-05-13Exp: 2022-09-13→ Common Stock (16,667 underlying) - 16,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $6.00From: 2018-12-07Exp: 2022-12-07→ Common Stock (16,667 underlying)
Footnotes (1)
- [F1]The reporting person acquired 21,053 Units, each Unit consisting of one share of Common Stock and a five year warrant at an exercise price of $5.70 per share. The purchase price for a Unit was $4.75 per Unit.
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001676461
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 6:07 AM ET
- Size
- 14.2 KB